X

News

Vamorolone (VBP15) First-in-patient Studies in Duchenne Muscular Dystrophy Published

Rockville, MD –  2 October 2018
A clinical trial of vamorolone in 48 boys with Duchenne muscular dystrophy entitled “Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug” has been More >

More >

ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy

Rockville, MD –  22 August 2018
ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy. More >

More >

Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy

Rockville, MD – 26 June 2018
Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy.

More >

More >

Finalists Selected – 3rd Annual BioHealth Capital Region Crab Trap Competition

– Winner to be announced during 2018 BioHealth Capital Region Forum –

ROCKVILLE, MARYLAND, April 12, 2018 – Five companies have been selected to present to a panel of investor judges and an audience of industry leaders during the 2018 More >